Arbutus Biopharma (ABUS)Rubric Capital Management LP added to its stake +5.05M shares

6.63M

Shares reported · +5.05M vs prior quarter

0.32%

Disclosed portfolio weight

$29.8M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 23, 2026Company filing · Form 8-K · ResultsReported its results
2. May 13, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. May 26, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 26, 2026, Arbutus Biopharma Corporation (the “Company”) held its 2026 Annual General and Special Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved the adoption of the Company’s 2026 Omnibus Share and Incentive Plan (the “2026 Plan”).”
2. Jul 15, 2026Company filing · Form 8-K · Agreement ended, Executive changeChanged a top executive or board member, and ended an important agreement (and 1 more item)“Pursuant to the Settlement Agreement with Moderna described in Item 1.02 above, Moderna made an aggregate $950 million noncontingent lump sum payment (the “Noncontingent Settlement Payment”) to Arbutus and Genevant on July 8, 2026.”
3. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Arbutus Biopharma

For Arbutus Biopharma, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABUS page.

How this filing works

• SEC Form 13F

Other disclosures at Arbutus Biopharma

• SEC Schedule 13DOct 5, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Feb 5, 2025
• SEC Form 4Feb 5, 2025
• SEC Form 4Feb 5, 2025
• SEC Form 4Feb 5, 2025

Everything OQRO holds on this company is on its ABUS page.